Objective:Effect of serum IL 2R on immunofunction were studied.Methods:Serum IL 2R and lymphocytic competence to PHA,IL 2,NK activity,LAK activity,subsets of T lymphocytes and delayed skin supersensitization were tested in four groups,including 30 normal controls,16 athletes,50 patients with lung cancer and 50 malignant lymphomas.The correlation between the tested immunofunction in each group were also studied.Results:In normal population,no correlations were found.Malignancies with high level of sIL 2R were negtively correlated with various immunofunctions,such ascytologic competence to IL 2,NK activity,LAK aitivity and number of CD 3.No significant correlation was found in cytologic competence to PHA and ratio of CD 4 and CD 8.Conclusion:sIL 2R is an important blocking factor for immunofunction,but under the interaction between various cytokines in the immunoregulatory network,its blockege is different with strong or week competence.

Recent innovations in nanomaterials inspire abundant novel tumor-targeting CRISPR-based gene therapies. However, the therapeutic efficiency of traditional targeted nanotherapeutic strategies is limited by that the biomarkers vary in a spatiotemporal-dependent manner with tumor progression. Here, we propose a self-amplifying logic-gated gene editing strategy for gene/H₂O₂-mediated/starvation multimodal cancer therapy. In this approach, a hypoxia-degradable covalent-organic framework (COF) is synthesized to coat a-ZIF-8 in which glucose oxidase (GOx) and CRISPR system are packaged. To intensify intracellular redox dyshomeostasis, DNAzymes which can cleave catalase mRNA are loaded as well. When the nanosystem gets into the tumor, the weakly acidic and hypoxic microenvironment degrades the ZIF-8@COF to activate GOx, which amplifies intracellular H⁺ and hypoxia, accelerating the nanocarrier degradation to guarantee available CRISPR plasmid and GOx release in target cells. These tandem reactions deplete glucose and oxygen, leading to logic-gated-triggered gene editing as well as synergistic gene/H₂O₂-mediated/starvation therapy. Overall, this approach highlights the biocomputing-based CRISPR delivery and underscores the great potential of precise cancer therapy.